Alluvi, formerly LY3414901, represents a exciting advancement in weight management. This combined-action glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist exhibits remarkable impact in early clinical data, with substantial reduction in weight